3 recruiting, 1 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Ziftomenib: new trials by email Literature Review of Ziftomenib trials Research Report on Ziftomenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2027-01-15 | 2026-11-09 |
| A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia ziftomenib - Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 6 | 2026-04-23 | 2026-06-03 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Kura Oncology, Inc. | 263 | 2019-09-12 | 2026-05-13 |
Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1)
Kura Oncology, Inc. (1) · Kyowa Kirin Co., Ltd. (1) · Tanja Andrea Gruber (1) · Uma Borate (1)
United States (3) · Canada (2) · Belgium (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1)
Tanja A Gruber, MD, PhD (1) · Uma M Borate, MBBS, MD, MSc (1)
PMID 33741715, PMID 34267079, PMID 39362248, PMID 40997296, PMID 41671463